Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$178.43 USD
-0.90 (-0.50%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $178.42 -0.01 (-0.01%) 5:56 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Quest Diagnostics Incorporated has a PEG ratio of 2.48 compared to the Medical - Outpatient and Home Healthcare industry's PEG ratio of 1.96.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DGX 178.43 -0.90(-0.50%)
Will DGX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, Addus HomeCare and The Pennant
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
Other News for DGX
Quest Diagnostics: Investing In Healthcare's Future Today
Notable healthcare headlines for the week: Pfizer, Novo Nordisk and JNJ in focus
DGX forms 50 Day Moving Average Support on October 3
50 Day Moving Average Support appears for DGX after 0.89% move
Barclays Raises Price Target for Quest Diagnostics (DGX) to $190 | DGX Stock News